FFS, So far 2023 looking good for AMRN. Looks like your TA charts are tracking well! Next stop? $2 plus? Something seems to be brewing and it’s reflected in the charts and the PPS. Settlement, cash positive Q4, stabilized scripts and cash burn, more markets in EU, IPE science gaining traction worldwide, several studies supporting REDUCE-IT results, CardioLink-9 and other URI/COVID results, BRAVE, a potential Hikma settlement and more. Let’s hope it continues.